NovaBay Pharmaceuticals Is Recognized As A New California 100 Business Innovator By Golden Capital Network & Hamilton Lane

By September 22, 2009

Novabay Pharmaceuticals, Inc. (NYSE-AMEX: NBY, http://www.novabaypharma.com), has been recognized as a New California 100 Business Innovator by Golden Capital Network and Hamilton Lane. New California 100 businesses are some of the most innovative companies in the state representing California’s commitment to innovation, entrepreneurship, and workforce competitiveness.

Approximately 100 companies throughout the State of California received this prestigious recognition from over 400 nominations. New California 100 Businesses will be recognized during a luncheon awards ceremony at 11:45 am-1:15 pm on September 22, 2009 at the New California 100 Conference in Sacramento’s Sheraton Grand Hotel.

New California 100 Businesses are market-leading technology companies who have been selected based on the uniqueness of their innovation, competitive advantages, and job and economic impact on California’s economy now and into the future.

“These innovators are powerful job-creating machines,” said Jon Gregory, CEO/President of Golden Capital Network. “We believe innovation and entrepreneurship are the drivers of economic growth in California and these Innovation All-Stars are models for our state.”

“I am very pleased that NovaBay has been recognized as one of California’s leading innovative companies,” said Ron Najafi, president and CEO of NovaBay. “Our pharmaceutical product candidates now being tested in human clinical trials offer the hope of addressing the growing crisis of antibiotic resistance. Modern medicine faces an urgent need to develop new classes of drugs that do not develop resistance to antibiotics and antiseptics, The Aganocide® compounds we are developing are an example of such drugs. They are bioequivalent to the natural anti-microbial compounds produced in white blood cells that have remained effective against invading pathogens for millions of years.”

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide® compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com

About Golden Capital Network and Hamilton Lane:

Golden Capital Network leads by stimulating economic vitality through early stage private equity investment, connecting innovative entrepreneurs, active investors, service providers, and policymakers to share the insights, risks, and rewards of innovative collaboration. Our purpose is to facilitate entrepreneur and investor networks to provide capital, expertise, and resources for building world-class companies. Golden Capital Network provides communities with the capabilities to maximize the value of their own social capital networks for accelerating their homegrown entrepreneurs. Since 1999, Golden Capital Network’s 1,000+ alumni companies have raised more than $1.3 billion in capital. Golden Capital Network alumni companies include NovaBay Pharma (IPO); InterVideo (IPO), StubHub (acquired by Ebay), Security Focus (acquired by Symantec); PowerSchool (acquired by Apple); MaxPreps (acquired CBS), Meridian Systems (acquired by Trimble), and Hanson Information Technology (acquired by Information Global Systems). Hamilton Lane is an independent financial institution that provides discretionary and non-discretionary private equity asset management services to sophisticated investors worldwide. Founded in 1991, Hamilton Lane has grown to over 110 employees, with over $94 billion in total assets under management and supervision including over $12 billion of assets under management for managed accounts. Hamilton Lane clients include a number of the world’s largest institutional investors, as well as many mid-sized and smaller institutions.

Investors:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

Media Contact:
WeissComm
Aimee Corso
310-780-2661
acorso@wcpglobal.com

TOP